IMP-RR is not a single standardized medical term but a combination of two widely used clinical trial abbreviations: IMP, which stands for Investigational Medicinal Product, and RR, which stands for Relative Risk (or, in some contexts, Risk Reduction). You’ll most often encounter this pairing in clinical trial reports and regulatory documents where researchers measure how much a new drug or therapy changes a patient’s risk of a specific outcome compared to a control group.
IMP: The Investigational Medicinal Product
An Investigational Medicinal Product is any drug, vaccine, or biological therapy being tested in a clinical trial but not yet approved for general use. This is the treatment under investigation. Before a new therapy can reach patients, it goes through multiple phases of testing, from small safety studies to large trials involving hundreds or thousands of participants. Throughout that process, the therapy is referred to as the IMP.
The term is standard in regulatory frameworks, particularly in documents submitted to agencies like the FDA and the European Medicines Agency. If you’ve come across “IMP-RR” in a study summary or trial report, the IMP portion simply identifies the experimental treatment being evaluated.
RR: Measuring Relative Risk
Relative risk is one of the most common ways researchers express how a treatment performs. The calculation is straightforward: divide the rate of a specific outcome (like a side effect or disease progression) in the treatment group by the rate of that same outcome in the control group. An RR of 1.0 means no difference between groups. An RR below 1.0 means the treatment group had a lower risk. An RR above 1.0 means higher risk.
For example, if 6% of patients taking the investigational drug experienced a stroke compared to 2% in the control group, the relative risk would be 3.0, meaning a threefold increase in stroke risk for the drug group. The FDA emphasizes that these figures should always be reported with a 95% confidence interval, which tells you the range of values that are statistically plausible. A narrow confidence interval means the estimate is precise; a wide one signals more uncertainty.
When RR is used in the “risk reduction” sense, it typically refers to the percentage decrease in risk. If a treatment drops the rate of an event from 10% to 6%, the relative risk reduction is 40%.
How IMP-RR Appears in Clinical Trials
Phase III trials, the large studies that determine whether a new treatment gets approved, rely heavily on relative risk calculations to compare the IMP against existing treatments or placebo. Regulatory guidance from the FDA recommends focusing on these comparative estimates rather than simple pass/fail hypothesis testing. The goal is to quantify how much better or worse the new therapy performs and how confident researchers can be in that number.
When trials pool data from multiple study sites or multiple studies, analysts stratify results by individual trial to avoid a statistical problem called Simpson’s Paradox, where combining data carelessly can reverse the apparent direction of an effect. The standard reporting format is the relative risk with its 95% confidence interval, broken down by trial.
A Practical Example: Proton Therapy Trials
To see how risk comparisons work in practice, consider a large Phase III trial comparing intensity-modulated proton therapy (IMPT) to standard photon-based radiation for head and neck cancer. In that trial, led by MD Anderson Cancer Center, 28% of proton therapy patients became dependent on a feeding tube during treatment compared to 42% of patients receiving conventional radiation. That’s a meaningful reduction in a side effect that directly affects quality of life. Similarly, 24% of proton therapy patients maintained their weight (losing less than 5%) versus only 14% in the standard treatment group.
These are the kinds of comparisons that relative risk captures. Rather than simply saying one treatment is “better,” the RR puts a number on the difference, letting patients and doctors weigh the magnitude of the benefit against factors like cost, availability, and individual health circumstances.
Why This Metric Matters for Patients
If you’ve encountered IMP-RR in a study you’re reading about a treatment you or someone you know is considering, the key thing to focus on is the direction and size of the relative risk. A relative risk of 0.5 for a serious side effect means the investigational treatment cut that risk in half compared to the control. A relative risk of 1.8 for tumor control means patients on the new treatment were nearly twice as likely to see their cancer controlled.
Context matters enormously. A 50% relative risk reduction sounds dramatic, but if the baseline risk was very small (say, dropping from 2% to 1%), the absolute benefit is modest. This is why regulatory reviewers and informed readers look at both relative and absolute numbers together. Trial reports that only highlight relative risk without providing the raw event rates can make small effects look larger than they are.
Pay attention to the confidence interval as well. If a study reports a relative risk of 0.7 with a confidence interval of 0.4 to 1.1, the range crosses 1.0, which means the data can’t rule out that there’s no real difference between groups. A result like 0.7 with a confidence interval of 0.5 to 0.9 is more convincing because the entire range stays below 1.0, consistently pointing toward a benefit.